Falk Ehmann

1.7k total citations
25 papers, 859 citations indexed

About

Falk Ehmann is a scholar working on Economics and Econometrics, Immunology and Statistics and Probability. According to data from OpenAlex, Falk Ehmann has authored 25 papers receiving a total of 859 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 10 papers in Immunology and 7 papers in Statistics and Probability. Recurrent topics in Falk Ehmann's work include Biosimilars and Bioanalytical Methods (10 papers), Statistical Methods in Clinical Trials (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Falk Ehmann is often cited by papers focused on Biosimilars and Bioanalytical Methods (10 papers), Statistical Methods in Clinical Trials (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Falk Ehmann collaborates with scholars based in Netherlands, Germany and Sweden. Falk Ehmann's co-authors include Marisa Papaluca, Christian K. Schneider, Iordanis Gravanis, Camille Vleminckx, Martina Weise, Markus Paulmichl, Marc Maliepaard, Marisa Papaluca‐Amati, Esa Heinonen and Niklas Ekman and has published in prestigious journals such as Blood, Nature Biotechnology and Nature Reviews Drug Discovery.

In The Last Decade

Falk Ehmann

24 papers receiving 813 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Falk Ehmann Netherlands 14 373 231 169 165 132 25 859
Jiang Liu United States 16 227 0.6× 75 0.3× 83 0.5× 446 2.7× 426 3.2× 43 1.5k
Yow‐Ming Wang United States 18 403 1.1× 63 0.3× 120 0.7× 226 1.4× 350 2.7× 54 1.0k
Jeff Allen United States 13 52 0.1× 164 0.7× 37 0.2× 229 1.4× 154 1.2× 40 805
Jill Kolesar United States 19 132 0.4× 33 0.1× 55 0.3× 329 2.0× 296 2.2× 68 948
Joseph C. Del Paggio Canada 13 73 0.2× 384 1.7× 18 0.1× 248 1.5× 87 0.7× 28 796
Bertrand Pourroy France 17 66 0.2× 27 0.1× 64 0.4× 294 1.8× 331 2.5× 47 823
Stephen M. Schleicher United States 19 194 0.5× 144 0.6× 61 0.4× 373 2.3× 609 4.6× 62 1.3k
Manuel Sánchez-Félix United States 14 69 0.2× 21 0.1× 50 0.3× 85 0.5× 242 1.8× 24 694
Ellen V. Sigal United States 10 43 0.1× 137 0.6× 26 0.2× 103 0.6× 81 0.6× 23 405
Umang Swami United States 21 176 0.5× 42 0.2× 16 0.1× 727 4.4× 468 3.5× 173 1.6k

Countries citing papers authored by Falk Ehmann

Since Specialization
Citations

This map shows the geographic impact of Falk Ehmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Falk Ehmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Falk Ehmann more than expected).

Fields of papers citing papers by Falk Ehmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Falk Ehmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Falk Ehmann. The network helps show where Falk Ehmann may publish in the future.

Co-authorship network of co-authors of Falk Ehmann

This figure shows the co-authorship network connecting the top 25 collaborators of Falk Ehmann. A scholar is included among the top collaborators of Falk Ehmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Falk Ehmann. Falk Ehmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blanquie, Oriane, et al.. (2025). Insights into new approach methodology innovation: an EMA perspective. Nature Reviews Drug Discovery. 24(5). 325–326. 4 indexed citations
2.
Blanquie, Oriane, et al.. (2025). New approach methodologies: EU regulatory horizons. Nature Reviews Drug Discovery. 24(8). 571–572. 3 indexed citations
3.
Vetter, Thorsten, et al.. (2024). Identifying and overcoming challenges in the EMA’s qualification of novel methodologies: a two-year review. Frontiers in Pharmacology. 15. 1470908–1470908.
4.
Cordo’, Valentina, et al.. (2024). Insights into Early Interactions on Innovative Developments with European Regulators. Therapeutic Innovation & Regulatory Science. 58(6). 1108–1119. 1 indexed citations
5.
Vass, Panna, et al.. (2023). Enabling technologies driving drug research and development. Frontiers in Medicine. 10. 1122405–1122405. 8 indexed citations
6.
Vetter, Thorsten, et al.. (2022). Biomarkers in Medicines Development—From Discovery to Regulatory Qualification and Beyond. Frontiers in Medicine. 9. 878942–878942. 14 indexed citations
7.
Bakker, Elisabeth, et al.. (2022). Biomarker Qualification at the European Medicines Agency: A Review of Biomarker Qualification Procedures From 2008 to 2020. Clinical Pharmacology & Therapeutics. 112(1). 69–80. 30 indexed citations
8.
Ehmann, Falk, et al.. (2021). Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency. Frontiers in Medicine. 8. 753187–753187. 22 indexed citations
9.
Ehmann, Falk, Jeroen Aerssens, & Rebecca Blanchard. (2020). Commentary on ICH guideline on genomic sampling and data management‐enabling opportunities in drug development and patient treatment. British Journal of Clinical Pharmacology. 86(8). 1454–1464. 3 indexed citations
10.
Ehmann, Falk, et al.. (2016). Nanomedicines in the EU—Regulatory Overview. The AAPS Journal. 18(6). 1576–1582. 56 indexed citations
11.
Ehmann, Falk, Krishna Prasad, Markus Paulmichl, et al.. (2015). Pharmacogenomic information in drug labels: European Medicines Agency perspective. The Pharmacogenomics Journal. 15(3). 201–210. 96 indexed citations
12.
Ehmann, Falk, et al.. (2015). Changes and determination of dosing recommendations for medicinal products recently authorised in the European Union. Expert Opinion on Pharmacotherapy. 16(6). 903–911. 6 indexed citations
13.
Papaluca, Marisa, et al.. (2015). White spots in pharmaceutical pipelines–EMA identifies potential areas of unmet medical needs. Expert Review of Clinical Pharmacology. 8(3). 353–360. 6 indexed citations
14.
Pignatti, Francesco, Falk Ehmann, Robert Hemmings, et al.. (2014). Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union. Clinical Cancer Research. 20(6). 1458–1468. 33 indexed citations
15.
Maliepaard, Marc, Charity Nofziger, Marisa Papaluca, et al.. (2013). Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nature Reviews Drug Discovery. 12(2). 103–115. 50 indexed citations
16.
Ehmann, Falk, Marco Amati, Tomas Salmonson, et al.. (2013). Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude. Clinical Pharmacology & Therapeutics. 93(5). 425–432. 28 indexed citations
17.
Phillips, Lawrence D., Barbara Fasolo, Hans Georg Eichler, et al.. (2013). Modelling the risk-benefit impact of H1N1 influenza vaccines. European Journal of Public Health. 23(4). 674–678. 10 indexed citations
18.
Schneider, Christian K., John-Joseph Borg, Falk Ehmann, et al.. (2012). Reply to In support of the European Union biosimilar framework. Nature Biotechnology. 30(8). 748–749. 4 indexed citations
19.
Schneider, Christian K., Camille Vleminckx, Iordanis Gravanis, et al.. (2012). Setting the stage for biosimilar monoclonal antibodies. Nature Biotechnology. 30(12). 1179–1185. 57 indexed citations
20.
Ehmann, Falk, Stefan Horn, Walter Fiedler, et al.. (2006). Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activatingRASmutations. Leukemia & lymphoma. 47(7). 1387–1391. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiang Liu Breakdown of academic impact, for papers by Yow‐Ming Wang Breakdown of academic impact, for papers by Jeff Allen Breakdown of academic impact, for papers by Jill Kolesar Breakdown of academic impact, for papers by Joseph C. Del Paggio Breakdown of academic impact, for papers by Bertrand Pourroy Breakdown of academic impact, for papers by Stephen M. Schleicher Breakdown of academic impact, for papers by Manuel Sánchez-Félix Breakdown of academic impact, for papers by Ellen V. Sigal Breakdown of academic impact, for papers by Umang Swami
Rankless by CCL
2026